Literature DB >> 26490991

The role of liver transplantation or resection for patients with early hepatocellular carcinoma.

Kuan-Chun Hsueh1,2, Ting-Ying Lee3, Chew-Teng Kor4, Tsung-Ming Chen5, Tzu-Ming Chang2, Shun-Fa Yang1,6, Chung-Bao Hsieh7.   

Abstract

Liver resection (LR) and liver transplantation (LT) are curative treatments for early hepatocellular carcinoma (HCC), although their performance remains debated. We compared the survival of patients with HCC conforming to the Milan criteria (MC) after LT and LR and analyzed factors affecting clinical outcomes. Between January 2006 and January 2013, 65 and 184 patients received LT and LR for HCCs fulfilling the MC, respectively. Overall survival (OS) and disease-free survival (DFS) rates were compared between the two groups. To investigate effects of liver function and living donor liver transplantation (LDLT) on survival, two subgroup analyses were performed and associations with OS and DFS were examined. We found that OS rates were higher after LT than after LR since 3 years postoperatively. DFS rates were significantly better after LT than after LR. Performance of LR, vascular invasion, and tumor multiplicity were associated with poor DFS, and factors affecting OS included the presence of vascular invasions, liver cirrhosis, and tumor multiplicity. In conclusion, despite of the effects of tumor characteristics on clinical outcomes, LT, including LDLT, should be considered the treatment of choice for patients with HCCs who met the MC. The role of LR is to identify poor prognostic factors through pathological examination.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver resection; Liver transplantation

Mesh:

Year:  2015        PMID: 26490991     DOI: 10.1007/s13277-015-4243-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  65 in total

1.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

3.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

4.  Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.

Authors:  Yoshisato Tanimoto; Hirotaka Tashiro; Hiroshi Aikata; Hironobu Amano; Akihiko Oshita; Tsuyoshi Kobayashi; Shintaro Kuroda; Hirofumi Tazawa; Shoichi Takahashi; Toshiyuki Itamoto; Kazuaki Chayama; Hideki Ohdan
Journal:  Ann Surg Oncol       Date:  2011-06-28       Impact factor: 5.344

Review 5.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

6.  Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.

Authors:  T Piardi; F Gheza; B Ellero; M L Woehl-Jaegle; D Ntourakis; M Cantu; E Marzano; M Audet; P Wolf; Patrick Pessaux
Journal:  Ann Surg Oncol       Date:  2011-12-17       Impact factor: 5.344

Review 7.  Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.

Authors:  Charing Ching Ning Chong; Grace Lai Hung Wong; Paul Bo San Lai
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era.

Authors:  Wei-Chen Lee; Kun-Ming Chan; Hong-Shiue Chou; Ting-Jung Wu; Chen-Fang Lee; Ruey-Shyang Soong; Tsung-Han Wu; Ching-Song Lee
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

9.  Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Authors:  Shinichi Ueno; Masahiko Sakoda; Fumitake Kubo; Kiyokazu Hiwatashi; Taro Tateno; Yoshiro Baba; Susumu Hasegawa; Hirohito Tsubouchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-03-20

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  9 in total

1.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

2.  [Inhibitory effect of Biejiajian pills against diethylnitrosamine-induced hepatocarcinogenesis in rats].

Authors:  Minghui Feng; Songqi He; Songze Huang; Jiaxin Lin; Huilin Yang; Jiaji Wang; Jie Pang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

3.  Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.

Authors:  Jin Hean Koh; Darren Jun Hao Tan; Yuki Ong; Wen Hui Lim; Cheng Han Ng; Phoebe Wen Lin Tay; Jie Ning Yong; Mark D Muthiah; Eunice X Tan; Ning Qi Pang; Beom Kyung Kim; Nicholas Syn; Alfred Kow; Brian K P Goh; Daniel Q Huang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 8.265

4.  MELD score and AST-to-platelet ratio index (APRI) predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study.

Authors:  Joy Sarkar; Thomas DeLeon; Linda L Wong
Journal:  Hepatoma Res       Date:  2017-05-09

5.  Liver resection for early hepatocellular cancer: Comparison of centers in 3 different countries.

Authors:  Linda L Wong; Brenda Y Hernandez; Yurii B Shvetsov; Yoichi Kawano; Zhao-You Tang; Jun-Fang Ji
Journal:  World J Hepatol       Date:  2016-11-08

6.  Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro.

Authors:  Qingmin Chen; Ludong Tan; Zhe Jin; Yahui Liu; Ze Zhang
Journal:  Biomed Res Int       Date:  2020-06-24       Impact factor: 3.411

7.  Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line.

Authors:  Yongxi Tong; Mingshan Wang; Haijun Huang; Jiajie Zhang; Yicheng Huang; Yingjun Chen; Hongying Pan
Journal:  Exp Ther Med       Date:  2019-09-19       Impact factor: 2.447

8.  MiR-129-5p inhibits liver cancer growth by targeting calcium calmodulin-dependent protein kinase IV (CAMK4).

Authors:  Zhengzhao Li; Junyu Lu; Guang Zeng; Jielong Pang; Xiaowen Zheng; Jihua Feng; Jianfeng Zhang
Journal:  Cell Death Dis       Date:  2019-10-17       Impact factor: 8.469

9.  KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells.

Authors:  Junli Zhang; Xiaohui Zhao; Xiaojuan Ma; Zengyan Yuan; Miao Hu
Journal:  Int J Mol Med       Date:  2020-08-25       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.